Table 1.
Demographic and Clinical Features of Adolescents and Young Adults with Diffuse Large B-Cell Lymphoma
| Characteristics | All patients, No. (%) |
|---|---|
| No. of patients | 90 |
| Median age at diagnosis, years | 33 |
| Age group | |
| 15–24 | 8 (9) |
| 25–39 | 82 (91) |
| Males | 51 (57) |
| Place of residence | |
| Lima province | 41 (46) |
| Other provinces | 49 (54) |
| Performance statusa | |
| <90 | 39 (43) |
| ≥90 | 51 (57) |
| Nodal involvement | 70 (78) |
| Extranodal involvement | 44 (49) |
| B symptoms | 52 (58) |
| Clinical stage | |
| I–II | 55 (61) |
| III–IV | 35 (39) |
| Frontline regimen | |
| R-CHOP | 69 (78) |
| R-EPOCH | 7 (8) |
| CHOP | 5 (6) |
| R-CHOEP | 3 (3) |
| CHOEP | 3 (3) |
| FAB/LMB | 2 (2) |
| Unknown | 1 |
| Radiotherapyb | 37 (41) |
| Relapse/refractory | 29 (32) |
| Second-line regimen | 24 (27) |
| HSCT after second line | 4 (4) |
| Treatment abandonment | 14 (16) |
a
Performance status was evaluated by Lansky or Karnofsky scales.
b
Radiotherapy treatment as a consolidation or palliative treatment.
CHOP, cyclophosphamide, vincristine, doxorubicin and prednisone; CHOEP, cyclophosphamide, vincristine, doxorubicin, etoposide, and prednisone; FAB/LMB, French-American-British/Lymphome Malins B regimen; HSCT, hematopoietic stem cell transplantation; R-CHOP, rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone; R-CHOEP, rituximab, cyclophosphamide, vincristine, doxorubicin, etoposide and prednisone; R-EPOCH, rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin.